April 16 Day 2 - 10 Co-conferences
Chair's opening remarks
Chair's opening remarks
Chair's opening remarks
- 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that’s translational to a universal solution
- The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities
- Newest research in universal influenza vaccines and their potential impact on the flu market
- Immunology and virology of HIV-1 infection and developing novel vaccine strategies
- How are non-profits and academics de-risking earlier staged vaccine research before further development?
- Strategy in collaborative models
- A new shift in how vaccines are developed, how does this compare to 10 years ago? Is there a new emphasis on testing in humans earlier?
- Pharma vision – is there a growing gap in end to end processing expertise?
-Who is CARB-X-What vaccines programs they are supporting -What they are looking for in a partner, public-private partnerships
FireChat 1 – FireChat 1 – Bacterial Vaccine
- How have non-medical exemptions affected vaccine uptake in the US?
- The vaccine education project: Laying the groundwork to ensure children and young adults are more accepting of vaccines in the future – what are the reasons that people are influenced by the anti-vaccine movement?
- Developing a vaccine education curriculum for physicians to increase vaccine acceptance
- What is the current and future role of digital/social media in shaping public perception around vaccination?
- How can the media be used as a tool to aid scientists in getting out their message accurately? How can scientists communicate with journalists more effectively?
- Most potential antigens identified in silico are not active in vivo
- Algorithms for prediction of good CTL epitopes in viral and model antigens are generally not predictive of good anti-cancer response
- CD8 response as measured ex vivo is not predictive of anti-tumor response (i.e. tumor regression) in vivo
- New rules for prediction are suggested
- A Phase 1 trial in patients with advanced ovarian cancers is ongoing
Dr Ana Fernandez-Sesma, Chair, Human Immunology Project Consortium & Professor, Icahn School Of Medicine, Mount Sinai
Senior representative, Medicago
Overcoming challenges in seasonal vaccine studies
FireChat 4 – DNA vaccine
Senior representative, Nipah Project Leader, PATH
Outsource manufacturing of your vaccine candidate: The do’s and don’ts
Senior representative, Wacker Biotech
- Latest trends and key considerations in vaccine development and manufacturing in emerging markets.
- Advancing bioprocessing technologies to serve domestic needs, more simply and affordably
- Single use systems and flexible and scalable technologies
- A case study how single use involves vaccine process development on a virus-like particles (VLPs) vaccine candidate in China
Senior representative, Sartorius-Stedim
Overcoming key supply chain challenges for vaccine shipments
Senior representative, hVIVO
Dr Matthew Memoli, Director, NIAID-NIH
- Understanding the mechanisms by which DC functions are disrupted by the tumor microenvironment
- Insights on innovative improvements in DC targeted vaccine platforms
- Methods for improving DC maturation, antigen presentation, antigen loading, selection and proliferation
- Alternatives to using monocyte-derived DCs
- How can a combination of this and other immunotherapies be used to overturn tumor-induced immune-suppression?
Innovations in cold chain equipment for immunization supply chains
Reserved for Viroclinics Biosciences
- Update on efficacy studies of the live attenuated dengue vaccine TV003/005
- Progress of the Butantan dengue Phase III clinical trial
- The dengue vaccine program at Merck
- WHO recommendations for Dengvaxia
We will present experimental work and process economy calculations, from AdV production in cell culture to purified bulk productAn efficient and scalable process for AdV production was developed from analysis of each process step
Identifying immune responses that predict disease protection
Mike Rush, Executive Director - Global Health Policy, Temptime Corporation
Dr Ted Prusik, Co-Founder, Senior Vice President, Temptime Corporation
-From Model Fitting to Machine Learning
-How both companies identified the initial match?-How the responsibilities of each party were determined-Lessons learned so far and what both parties hope to achieve
- Where are we on dengue, malaria, chikungunya, yellow fever and Zika
- How can vaccines and vector control be integrated and used synergistically and has it worked?
-Aseptic, purified, cryopreserved sporozoites for CHMI (“challenge in a bottle”)-Expansion of research capabilities in Africa-Ethical considerations of CHMI in HIV+ populations
- Expanding vaccine effectiveness with needle-free delivery
-Objectives of a public-private partnership -How were the partners resourced-What was the outcome of the collaboration
Clinical development of a GM-CSF expressing oncolytic adenovirus, for the treatment of non-muscle invasive bladder cancer
- Clinical milestone in skin vaccination: Combining the P.L.E.A.S.E.® epidermal system with the dry-patch technology boosts immunogenicity in an adjuvant-free setting
-Bioethics of using the human challenge model-Background information on the original report for zika vaccine development-Epidemiology of zika today-How has the landscape changed
- Microprojection array patch clinical study with influenza vaccine: Demonstration of efficacy, dose reduction, and high temperature stability
- Benefits of administration via nasal spray
- Vaccine efficacy
- Summary of field trial data and findings
Session led by:
-How are the studies done?-How are the models developed and used?-How are CHIMS becoming more commercially used?-Why do subjects volunteer?
Philip Krause, Deputy Director, U.S. Food and Drug Administration
Alternative delivery system technology showcase
Mucosal delivery routes
- An overview of preclinical, phase 1 data and recent phase 2 results
- Development aspects unique to RSV and immunologic correlates
- Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval
- Accessing emerging / re-emerging diseases in difficult or remote regions of the world is immensely complex.
- Learn what expeditionary research is and how to support it (staff, technology, logistics)
- How do you switch from a briefcase to a backpack
- How does different routes of delivery influence the immunological outcome?
- Effectiveness and usability
last published: 25/Mar/19 10:45 GMT
Get Involved At
World Vaccine Congress Washington